258 related articles for article (PubMed ID: 20039313)
21. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
Fong D; Bisson M; Laberge G; McManus S; Grenier G; Faucheux N; Roux S
Cell Signal; 2013 Apr; 25(4):717-28. PubMed ID: 23313128
[TBL] [Abstract][Full Text] [Related]
22. Bone morphogenetic protein 2 enhances PGE(2)-stimulated osteoclast formation in murine bone marrow cultures.
Blackwell KA; Hortschansky P; Sanovic S; Choudhary S; Raisz LG; Pilbeam CC
Prostaglandins Other Lipid Mediat; 2009 Dec; 90(3-4):76-80. PubMed ID: 19744575
[TBL] [Abstract][Full Text] [Related]
23. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
24. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells.
Yamada T; Yamazaki H; Yamane T; Yoshino M; Okuyama H; Tsuneto M; Kurino T; Hayashi S; Sakano S
Blood; 2003 Mar; 101(6):2227-34. PubMed ID: 12411305
[TBL] [Abstract][Full Text] [Related]
25. Regulatory mechanisms of osteoblast and osteoclast differentiation.
Katagiri T; Takahashi N
Oral Dis; 2002 May; 8(3):147-59. PubMed ID: 12108759
[TBL] [Abstract][Full Text] [Related]
26. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
27. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
28. Bone Morphogenetic Protein-2 Promotes Osteoclasts-mediated Osteolysis via Smad1 and p65 Signaling Pathways.
Miao X; Yuan J; Wu J; Zheng J; Zheng W; Wang F; Wang C; Li X; Liu S; Shi Z; Li J
Spine (Phila Pa 1976); 2021 Feb; 46(4):E234-E242. PubMed ID: 33156278
[TBL] [Abstract][Full Text] [Related]
29. BMP-2 and titanium particles synergistically activate osteoclast formation.
Sun SX; Guo HH; Zhang J; Yu B; Sun KN; Jin QH
Braz J Med Biol Res; 2014 Jun; 47(6):461-9. PubMed ID: 24820069
[TBL] [Abstract][Full Text] [Related]
30. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory Effects of Combined Bone Morphogenetic Protein 2, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor on Osteoclast Differentiation and Activity.
Wu H; Yin G; Pu X; Wang J; Liao X; Huang Z
Tissue Eng Part A; 2021 Nov; 27(21-22):1387-1398. PubMed ID: 33632010
[TBL] [Abstract][Full Text] [Related]
32. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
33. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF.
Fujita K; Janz S
Mol Cancer; 2007 Oct; 6():71. PubMed ID: 17971207
[TBL] [Abstract][Full Text] [Related]
34. Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.
Kim T; Kim K; Lee SH; So HS; Lee J; Kim N; Choi Y
J Biol Chem; 2009 May; 284(22):15308-16. PubMed ID: 19336404
[TBL] [Abstract][Full Text] [Related]
35. PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts.
Hikata T; Takaishi H; Takito J; Hakozaki A; Furukawa M; Uchikawa S; Kimura T; Okada Y; Matsumoto M; Yoshimura A; Nishimura R; Reddy SV; Asahara H; Toyama Y
Blood; 2009 Mar; 113(10):2202-12. PubMed ID: 18952894
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
37. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Mochizuki S; Tomoyasu A; Yano K; Goto M; Murakami A; Tsuda E; Morinaga T; Higashio K; Udagawa N; Takahashi N; Suda T
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3597-602. PubMed ID: 9520411
[TBL] [Abstract][Full Text] [Related]
38. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin.
Abe E; Yamamoto M; Taguchi Y; Lecka-Czernik B; O'Brien CA; Economides AN; Stahl N; Jilka RL; Manolagas SC
J Bone Miner Res; 2000 Apr; 15(4):663-73. PubMed ID: 10780858
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism.
Zou W; Hakim I; Tschoep K; Endres S; Bar-Shavit Z
J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):70-83. PubMed ID: 11500955
[TBL] [Abstract][Full Text] [Related]
40. Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism.
Sivagurunathan S; Pagel CN; Loh LH; Wijeyewickrema LC; Pike RN; Mackie EJ
J Mol Endocrinol; 2013 Jun; 50(3):347-59. PubMed ID: 23419317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
